-
Innovation Ranking
NewInnovation Ranking – Cellectar Biosciences Inc
Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product includes CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric...
-
Product Insights
NewNet Present Value Model: Cellectar Biosciences Inc’s Iopofosine i-131
Empower your strategies with our Net Present Value Model: Cellectar Biosciences Inc's Iopofosine i-131 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Cellectar Biosciences Inc’s Iopofosine i-131
Empower your strategies with our Net Present Value Model: Cellectar Biosciences Inc's Iopofosine i-131 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linvoseltamab in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Refractory Multiple Myeloma Drug Details: Linvoseltamab (REGN-5458) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Mantle Cell Lymphoma Drug Details: Iopofosine I-131...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Marginal Zone B-cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Multiple Myeloma (Kahler Disease) Drug Details:...